These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 33343375)

  • 1. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.
    Peng C; Stewart AG; Woodman OL; Ritchie RH; Qin CX
    Front Pharmacol; 2020; 11():603926. PubMed ID: 33343375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Proc Nutr Soc; 2016 Feb; 75(1):1-9. PubMed ID: 26282529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease, an Overview.
    Nd AM
    Integr Med (Encinitas); 2019 Apr; 18(2):42-49. PubMed ID: 31341444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.
    Henkel J; Coleman CD; Schraplau A; Jӧhrens K; Weber D; Castro JP; Hugo M; Schulz TJ; Krämer S; Schürmann A; Püschel GP
    Mol Med; 2017 May; 23():70-82. PubMed ID: 28332698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAFLD and NASH: The Metabolically Diseased Liver.
    Armandi A; Schattenberg JM
    Handb Exp Pharmacol; 2022; 274():253-267. PubMed ID: 34811578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine models provide insight to the development of non-alcoholic fatty liver disease.
    Reid DT; Eksteen B
    Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
    Noureddin M; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".
    Manti S; Romano C; Chirico V; Filippelli M; Cuppari C; Loddo I; Salpietro C; Arrigo T
    Hepat Mon; 2014 May; 14(5):e17641. PubMed ID: 24829591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical models of non-alcoholic fatty liver disease.
    Santhekadur PK; Kumar DP; Sanyal AJ
    J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
    World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.